Doxy-PEP: what it is, who it is for, and what it does not do.

Doxycycline, or “doxy”, is a common antibiotic. PEP stands for post-exposure prophylaxis: prevention taken after a possible exposure rather than before it. Put together, doxy-PEP means taking a prescribed dose of doxycycline within 72 hours after sex to lower the chance that a bacterial STI takes hold (Preventing STIs with Doxy PEP, CDC, 2026).

It is a prescription medicine, and it works differently from the tools most people already know. Condoms work in the moment. PrEP is taken ahead of time and protects against HIV only. Doxy-PEP is taken afterwards and acts only on certain bacteria. It is also not the same thing as HIV PEP, the emergency HIV medicine someone might need after a condom breaks.

The evidence for doxy-PEP is strong in the groups it was tested in (MMWR guidelines, 2024). It is also new enough that researchers are still watching how it behaves over years, and who else it might help. This guide sets out what is known, what is not, and why the answer to “should I take it?” always starts with a clinician.

CDC’s 2024 clinical guidelines summarise three large randomised trials in gay, bisexual and other men who have sex with men and transgender women. In them, doxy-PEP reduced syphilis and chlamydia infections by more than 70% and gonorrhea by about 50% (MMWR guidelines, 2024).

One of those trials, DoxyPEP, enrolled 501 participants who had had a bacterial STI in the previous year. Among those taking HIV PrEP, an STI was diagnosed at 10.7% of quarterly check-ups in the doxycycline group, against 31.9% in the group receiving standard care. The authors summarised it as a combined drop of about two thirds (Luetkemeyer et al., NEJM, 2023).

What it does not do matters just as much. In CDC’s words, doxy-PEP “can only help prevent chlamydia, syphilis, and gonorrhea. It does not prevent other common STIs, like HIV, or herpes” (CDC, 2026). Because it only acts on those bacteria, viral infections such as HPV and hepatitis are outside its reach too; condoms, PrEP and vaccines are the tools for those.

CDC recommends that clinicians discuss doxy-PEP with all gay, bisexual and other men who have sex with men, and transgender women, who have had at least one bacterial STI (syphilis, chlamydia or gonorrhea) in the last 12 months, and offer it through shared decision-making (CDC guidance for clinicians, 2024). Clinicians may also discuss it with people in those groups who have not had a recent STI but whose sex lives carry a higher chance of exposure.

The World Health Organization issued its first doxy-PEP recommendation on May 28, 2026, for the same two groups: men who have sex with men and transgender women. WHO asks that it be offered within comprehensive sexual health care, prioritising people with recent or repeated STIs, and with monitoring for antibiotic resistance (WHO, 2026).

For a mixed lifestyle audience, the practical reading is this. A bisexual man who has sex with men and has had a bacterial STI in the past year is squarely in the group both bodies describe, and it is worth raising with a clinician. For everyone else, read on.

CDC’s guidelines state that no recommendation can be given at this time on doxy-PEP for cisgender women, cisgender heterosexual men, transgender men, or other queer and nonbinary people, because the evidence is not enough to weigh the benefits against the harms (MMWR guidelines, 2024). That is not the same as saying it is harmful for those groups. It means the question has not been answered yet.

The one completed trial in cisgender women enrolled 449 women aged 18 to 30 in Kenya who were taking HIV PrEP. It found no significant reduction in STIs with doxy-PEP. Hair testing found doxycycline in only 29% of the samples checked, which suggests many participants were not taking the doses, though researchers say biological differences still need to be explored (Stewart et al., NEJM, 2023; MMWR, 2024).

CDC says studies in other groups, including cisgender women, are vital and that it will update its guidance as data arrive (CDC, 2024). Until then, if you are a straight or bisexual woman or a straight man, the proven tools are the familiar ones: condoms, regular testing, vaccines and, for HIV, PrEP. A clinician can still talk you through what is known for your situation. The answer does doxy-PEP work for women? goes further into that question.

Doxy-PEP is prescribed so that you can keep doses on hand and take a dose as your clinician directs, within the 72-hour window described in CDC guidance. The exact dose, timing and limits are set out by your clinician, who also explains how to take it to reduce stomach upset and sun sensitivity. We do not give dosing instructions here, because they belong in a consultation, not a web page.

Two things about using it are worth knowing in advance. First, the follow-up: CDC advises seeing your clinician every three to six months for HIV and STI testing, a review of side effects, and a decision about whether doxy-PEP is still right for you. Second, the limits: CDC notes that the dose used for prevention is not strong enough to treat an STI you already have, so a positive test still needs proper treatment (CDC, 2026). And a prescription is personal; CDC asks people not to share it.

CDC says that in general people can take doxycycline without significant side effects. The common ones are nausea, upset stomach, diarrhea and sensitivity to the sun (CDC, 2026). In the French IPERGAY study, stomach and bowel side effects were reported by 53% of people taking doxy-PEP against 41% of those not taking it, and the DoxyPEP trial attributed no serious adverse events to doxycycline (MMWR, 2024).

The bigger question is antibiotic resistance, meaning bacteria becoming harder to treat with the drugs designed to kill them. In the DoxyPEP trial, tetracycline-resistant gonorrhea was found in 5 of 13 participants with a gonorrhea culture in the doxycycline groups and 2 of 16 in the standard-care groups, small numbers but worth watching (Luetkemeyer et al., 2023). CDC’s guidelines also report that among people taking doxy-PEP, overall nasal carriage of Staphylococcus aureus fell, but the share carrying a tetracycline-resistant strain rose from 5% to 13% (MMWR, 2024).

Researchers are also still learning about long-term effects on the microbiome, the helpful bacteria in the gut and on the skin. This is why CDC’s guidelines focus doxy-PEP on the groups where it has been proven to help, rather than on everyone, and why WHO asks for resistance monitoring: it keeps antibiotic use to the people most likely to benefit (CDC, 2024; WHO, 2026).

Doxy-PEP is an antibiotic taken after sex. It lowers the chance of syphilis, chlamydia and some gonorrhea, for the groups in which it has been tested.

PrEP is HIV medicine taken before any exposure, as pills or injections. It prevents HIV and nothing else (Preventing HIV with PrEP, CDC, 2026). See our PrEP guide.

HIV PEP is emergency medicine after a possible HIV exposure, such as a broken condom, and it must start within 72 hours. CDC is clear that it is not a substitute for regular prevention (Preventing HIV with PEP, CDC, 2024).

Condoms work in the moment against HIV and many STIs, and less well against infections that spread through skin or sores. Vaccines prevent hepatitis B and HPV ahead of time (STI prevention, CDC, 2024), and CDC’s doxy-PEP page also suggests asking about hepatitis A.

Doxy-PEP is an add-on, not a replacement. CDC frames it as one part of a comprehensive approach that includes regular testing, PrEP for HIV where it fits, vaccination and condoms. It works best as one layer among several.